Reported 7 days ago
With Donald Trump returning to the White House and the Republican party gaining control of Congress, predictions suggest a surge in mergers and acquisitions (M&A) due to easing interest rates and potential regulatory changes. Viking Therapeutics, a clinical-stage pharmaceutical company targeting the weight loss market, is highlighted as a prime acquisition candidate, potentially attracting offers around $15 billion despite its current market cap of $6.2 billion.
Source: YAHOO